Latest news with #TerraPowerIsotopes
Cision Canada
10 hours ago
- Business
- Cision Canada
AtomVie Global Radiopharma and TerraPower Isotopes Announce Strategic Supply Agreement for Actinium-225 to Advance Radiopharmaceutical Development and Manufacturing
HAMILTON, ON, June 17, 2025 /CNW/ - AtomVie Global Radiopharma (AtomVie) and TerraPower Isotopes, LLC (TPI) today announced a supply agreement under which TPI will provide its high-quality Actinium-225 (Ac-225) 1 isotope to support AtomVie's contract development and manufacturing (CDMO) activities in radiopharmaceuticals, providing an added value to its clients with Ac-225-based programs. The aim is to strengthen the supply chain and accelerate the development and commercialization of targeted radiopharmaceutical therapies for cancer and other diseases. The agreement supports both AtomVie's early and late-stage development programs with pharmaceutical partners for global clinical and commercial pipelines. By securing a reliable supply of Ac-225, the agreement enhances flexibility and responsiveness across the entire product development lifecycle. "We are pleased to work with TerraPower Isotopes to ensure a supply of Actinium-225 for our clients. This reinforces our ability to meet the evolving needs of pharmaceutical partners by supporting their programs from development through to commercial supply. Together, we are advancing innovative therapies and improving patients' lives worldwide with high-quality radiopharmaceuticals." said Bruno Paquin, CEO of AtomVie. "Collaborating with AtomVie allows us to help advance the next generation of targeted radiopharmaceutical therapies. By combining access to our extremely pure Ac-225 with their development and manufacturing capabilities, we are proud to play a pivotal role in expanding treatments that have the potential to improve outcomes for patients." said Scott Claunch, President of TerraPower Isotopes. This supply agreement reflects the shared commitment of both organizations to advancing nuclear medicine innovation and expanding global access to cutting-edge radiotherapies. About AtomVie Global Radiopharma (AtomVie) AtomVie is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality and logistics combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies to the commercial marketplace. AtomVie currently serves international clients conducting clinical studies in over 25 countries worldwide. AtomVie is currently building a new state-of-art purpose-built 72,300 sq ft facility, set to launch at the end of 2025. For more information, visit About TerraPower Isotopes (TPI) TerraPower Isotopes is bringing the next generation of isotopes to market. A subsidiary of TerraPower, a leading nuclear innovation company, TerraPower Isotopes applies innovative expertise and proven development methods to targeted alpha therapy. The company supports medical research by developing advanced radioisotope generators that enable the efficient and automated extraction of rare isotopes with life-saving potential. TerraPower Isotopes is increasing global access to Actinium-225, which may improve cancer treatments by destroying targeted cancer cells with minimal damage to healthy tissue. Learn more at About TerraPower TerraPower is a leading nuclear innovation company that strives to improve the world through nuclear energy and science. Since it was founded by Bill Gates and a group of like-minded visionaries, TerraPower has emerged as an incubator and developer of ideas and technologies that offer energy independence, environmental sustainability, medical advancement and other cutting-edge opportunities. It accepts and tackles some of the world's most difficult challenges. Behind each of its innovations and programs, TerraPower actively works to bring together the strengths and experiences of the world's public and private sectors to answer pressing global needs. SOURCE AtomVie Global Radiopharma Inc.
Yahoo
20-02-2025
- Health
- Yahoo
Everett lab works on drug could cure some cancerous tumors
Scientists in Everett are trying to develop part of a drug that could potentially cure certain tumorous cancers. Bill Gates' TerraPower Isotopes lab is the first to use part of a radioactive material to fight disease. Uranium-233 was originally meant to be used as a powerful Cold War weapon but was quickly deemed too dangerous. The material has been sitting in a heavily guarded armed bunker for decades. Terrapower Isotopes President Scott Claunch tells us if used in its original capacity, uranium-233 is deadly. 'It was thought at the time as a potential source for fuel for nuclear reactors,' Claunch said. Now scientists want to use it to save lives instead. 'It works very specifically to deposit directly to the cancerous cells,' Claunch said. TerraPower Isotopes is using the element broken down to its lowest form, also known as actinium 225. By extracting the actinium, the drug developers can turn it into part of an experimental drug. 'When it does that, the actinium destroys the cancerous cells and protects the healthy tissue,' Claunch said. Protecting the healthy cells is the main goal. By only targeting the sick cancerous cells and not attacking the good ones, the outcomes and impacts of treatment are very different. 'This targeted alpha therapy really brings hope for the patient,' Claunch said. 'It destroys cancer at the cellular level and the side effects are minimal.' Because of that careful attention to detail, hundreds of patients across the world are currently part of a phase three trial for a drug. In one case, a male patient's body was shown riddled with metastasized prostate cancer. After a few months of treatment with the actinium drug, the tumors are gone according to his scans. In this case, shocking results were clear. The American Cancer Society data shows more than 616,000 people will die of Cancer in the U.S. in 2025. This is a number scientists in Everett are desperate to lower. 'It's difficult, rewarding, motivating, and the team of scientists and operators are some of the best in class people being tasked with solving these issues to enable a future without cancer or keep cancer at bay,' Claunch said. If the drug makes it through all needed trials, it then will be submitted to the FDA for approved. Leaders tell us they hope this could be available to all cancer patients by 2028.
